FDA Peptide Ban Lifted: 14 Peptides Reclassified in 2026
RFK Jr. announced 14 peptides are moving off the FDA's "do not compound" list. Which peptides return, which stay restricted, and what it actually means.
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides banned from compounding pharmacies would be moved off the FDA's restricted list — making it the single largest reversal in U.S. peptide regulatory history. If it goes through as described, peptides that have been legally off-limits since 2023 would once again be available through licensed compounding pharmacies with a prescription. The FDA peptide ban lifted in 2026 would affect millions of patients, clinicians, and compounding pharmacies. It's a big deal. But there's an equally important part of this story that most coverage is leaving out.
No formal FDA rule has actually changed yet.
Kennedy's statement signals intent. It does not represent completed regulatory action. No Federal Register notice has been issued. No updated list has been published. And the specific peptides involved, the timeline, and the implementation process all remain unconfirmed.
This article breaks down exactly what was said, what it means legally, which peptides are expected to be affected, and what you should — and shouldn't — do right now. It builds on our complete 2025-2026 regulatory timeline and draws on reporting from Gizmodo, PolitiFact, Inc., and legal analysis from LumaLex Law.
What Happened: The February 27, 2026 Announcement
The announcement didn't come through a press release, an FDA bulletin, or a Federal Register filing. It came on the Joe Rogan Experience, Episode #2461 — the most-listened-to podcast in the world. That's worth noting, because regulatory policy shifts of this magnitude are typically communicated through official government channels, not media appearances.
During the conversation, Kennedy said that approximately 14 of the 19 peptides currently on the FDA's Category 2 ("do not compound") list would be moved to Category 1, restoring their eligibility for legal compounding. His core argument: the FDA was legally required to identify a specific safety signal to justify placing each peptide on the restricted list, and for most of them, no such signal existed. The original restrictions, he argued, were based on a lack of efficacy data — not evidence of actual harm. That's a different standard, and it's one the FDA wasn't supposed to be using.
"My hope is that they're going to get moved to a place where people have access from ethical suppliers," Kennedy said.
He also made a candid admission about what the ban had done: "We created the gray market." By cutting off legal access through compounding pharmacies, the FDA had pushed patients toward unregulated online vendors selling peptides as "research chemicals" with zero pharmaceutical oversight.
Gizmodo, Inc., Newser, and PolitiFact all published coverage within days.
But here's what Kennedy didn't say: the specific timeline for formal reclassification, the exact list of 14 peptides, or the mechanism through which the change would be implemented. Those details — the ones that actually matter for legal status — remain open.
The Backstory: How 19 Peptides Got Banned in the First Place
To understand why this reversal is significant, you need to understand the system it's reversing.
The FDA maintains a set of lists that govern which substances compounding pharmacies can and can't use. The relevant categories:
- Category 1: Eligible for compounding under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Pharmacies can legally prepare these substances with a valid prescription.
- Category 2: Identified as posing "significant safety risks." Compounding is prohibited.
- Category 3: Insufficient data to evaluate. Under ongoing review.
These lists are maintained through the FDA's Bulk Drug Substances Used in Compounding framework, governed by the agency's interim policy on compounding.
The 2023 Crackdown
Starting in September 2023, the FDA began moving popular peptides from Category 1 to Category 2 at a pace the compounding industry had never seen. By February 2024, 17 peptides had been placed on the restricted list. Additional peptides followed through December 2024, bringing the total to 19.
We covered this in detail in our analysis of the FDA's peptide compounding crackdown. At the time, it represented the most restrictive compounding environment for peptides in U.S. history.
The FDA's stated reasons for the restrictions included:
- Immunogenicity concerns — the risk that injectable peptides could trigger immune reactions
- Manufacturing impurity risks — compounding pharmacies may not adequately control for contaminants
- Lack of large-scale human clinical trial data — most peptides on the list had only preclinical or limited clinical evidence
- Specific documented adverse events — for some peptides, notably GHRP-2, the FDA cited reports of serious adverse events including deaths
The Industry Pushback
The restrictions didn't go unchallenged. Compounding pharmacy groups argued the FDA had overstepped its authority. The Outsourcing Facilities Association filed lawsuits. Clinicians who had been prescribing these peptides for years argued that no specific safety signal justified blanket restrictions for most of the affected substances.
And then there was the unintended consequence that Kennedy would later acknowledge on Rogan: the ban drove patients to unregulated gray market vendors. Instead of getting peptides from pharmacies operating under USP 795/797 standards with sterility testing and oversight, patients were ordering from websites selling "research chemicals" — no prescription required, no quality control, no accountability. The FDA's own enforcement data reflected the scale of the problem: warning letters to peptide vendors increased dramatically during FY2025, a roughly 50% year-over-year surge.
The 14 Peptides Expected to Return to Legal Compounding
Based on Kennedy's announcement and reporting from multiple outlets, the following 14 peptides are expected to move from Category 2 to Category 1. They're organized here by therapeutic category.
A note on this list: The specific peptides named below are based on Kennedy's announcement and reporting from multiple news outlets and regulatory analysts. The formal FDA reclassification list has not been published as of March 7, 2026. The actual list may differ from what's been reported. We will update this article when the official list is released.
Tissue Repair and Recovery
1. BPC-157 (Body Protection Compound-157)
BPC-157 is probably the most talked-about peptide on this list. It's been studied in preclinical models for gut healing, tendon repair, musculoskeletal recovery, and inflammation reduction. The research base is extensive — BPC-157 activates the VEGFR2 pathway involved in angiogenesis (new blood vessel formation) — but it comes with a significant caveat: there are no published human clinical trials. Everything we know comes from animal and in vitro studies.
That said, its popularity among clinicians and patients made it one of the most visible casualties of the 2023 ban. Its expected return to Category 1 is one of the most anticipated reclassifications.
2. TB-500 (Thymosin Beta-4 Fragment)
TB-500 is a synthetic fragment of the naturally occurring protein Thymosin Beta-4. It's been studied in animal models for muscle repair, flexibility, wound healing, and recovery. Athletes and patients with musculoskeletal injuries drove much of the pre-ban demand.
3. GHK-Cu (Copper Peptide)
GHK-Cu is a naturally occurring peptide that declines with age. It's been studied for skin rejuvenation, wound healing, and anti-aging applications. The irony of its Category 2 placement: topical GHK-Cu products remained widely available and unaffected by the ban. Only the injectable form was restricted — a distinction that struck many observers as inconsistent.
Immune Support
4. Thymosin Alpha-1
Thymosin Alpha-1 has the strongest clinical evidence base of any peptide on this list. It's approved as a pharmaceutical in over 30 countries outside the United States for conditions including hepatitis B, hepatitis C, and as an adjunct cancer therapy. Its placement on the Category 2 list was one of the most controversial decisions in the 2023 crackdown, precisely because it already had a global regulatory track record.
5. KPV (Lysine-Proline-Valine)
KPV is a tripeptide derived from alpha-melanocyte stimulating hormone (alpha-MSH). It's been studied for anti-inflammatory effects, particularly in gut health and skin inflammation. Preclinical data suggests it may modulate inflammatory bowel conditions, though human clinical data is limited.
Metabolic Health and Body Composition
6. AOD-9604
AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) that's been studied for fat metabolism and body composition. There's an interesting wrinkle here: AOD-9604 received GRAS (Generally Recognized as Safe) status from the FDA for use in food products. The fact that the same agency considered it safe enough for food but too dangerous for compounding under medical supervision was a point of friction throughout the ban period.
7. MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA Type-C)
MOTS-C is a mitochondrial-derived peptide — meaning it's encoded by mitochondrial DNA, not nuclear DNA. Researchers have described it as an "exercise mimetic" for its effects on metabolic regulation and insulin sensitivity. It's a newer entry in the peptide world compared to compounds like BPC-157, but interest has grown rapidly.
Cognitive Function and Neuroprotection
8. Selank
Selank is a synthetic analog of tuftsin, an immunomodulatory peptide. It's been studied for anxiety reduction, cognitive performance, and immune modulation. Selank is approved for clinical use in Russia. It was one of five peptides removed from Category 2 and sent to the Pharmacy Compounding Advisory Committee (PCAC) for review in September 2024 — an earlier sign that the FDA's position on certain peptides was already shifting.
9. Semax
Semax is a synthetic analog of adrenocorticotropic hormone (ACTH). It's been studied for cognitive function, neuroprotection, ADHD, and stroke recovery. Like Selank, it's approved for clinical use in Russia and Ukraine. The two are often discussed together as the "Russian nootropic peptides."
Longevity and Anti-Aging
10. Epitalon (Epithalon)
Epitalon is a synthetic version of Epithalamin, a peptide naturally produced by the pineal gland. It's been studied for its potential to activate telomerase — the enzyme that maintains telomere length, a marker associated with biological aging. The longevity and anti-aging community drove much of the demand for Epitalon before the ban.
Growth Hormone Secretagogues
11. CJC-1295
CJC-1295 is a growth hormone-releasing hormone (GHRH) analog studied for its effects on growth hormone release, body composition, and recovery. It was one of five peptides sent to the PCAC for review in September 2024, and PCAC reviewed it under Section 503A in December 2024. That prior movement through the advisory process puts CJC-1295 among the peptides closest to formal reclassification.
12. Ipamorelin
Ipamorelin is a selective growth hormone secretagogue — meaning it stimulates GH release without significantly affecting cortisol or prolactin levels, which differentiates it from older secretagogues like GHRP-2 and GHRP-6. It was also sent to PCAC in September 2024 and reviewed in October 2024. Like CJC-1295, it's often used in combination protocols for body composition and recovery.
Hormonal and Sleep
13. Kisspeptin-10
Kisspeptin-10 is a naturally occurring neuropeptide involved in gonadotropin-releasing hormone (GnRH) signaling. It's been studied for reproductive hormone regulation and fertility. Its inclusion on the restricted list was questioned by endocrinologists given its physiological role in normal reproductive function.
14. The Unconfirmed 14th Peptide
The identity of the final peptide varies across sources. Some analysts list Emideltide (a Thymalin analog), others cite DSIP (Delta Sleep-Inducing Peptide), and some include Sermorelin or Tesamorelin. Until the FDA publishes the formal list, this spot remains uncertain. We'll update this section when official confirmation is available.
Summary Table: 14 Peptides Expected to Return
| Peptide | Category | Primary Research Areas |
|---|---|---|
| BPC-157 | Tissue Repair | Gut healing, tendon repair, inflammation |
| TB-500 | Tissue Repair | Muscle repair, wound healing, recovery |
| GHK-Cu | Tissue Repair | Skin rejuvenation, wound healing, anti-aging |
| Thymosin Alpha-1 | Immune Support | Immune modulation, hepatitis, cancer adjunct |
| KPV | Immune Support | Anti-inflammatory, gut health |
| AOD-9604 | Metabolic | Fat metabolism, body composition |
| MOTS-C | Metabolic | Metabolic regulation, insulin sensitivity |
| Selank | Cognitive | Anxiety, cognition, immune modulation |
| Semax | Cognitive | Neuroprotection, cognition, ADHD |
| Epitalon | Longevity | Telomerase activation, anti-aging |
| CJC-1295 | GH Secretagogue | Growth hormone release, body composition |
| Ipamorelin | GH Secretagogue | Growth hormone release, sleep quality |
| Kisspeptin-10 | Hormonal | Reproductive hormone regulation, fertility |
| TBD (14th unconfirmed) | Varies | See note above |
Understanding Category 1 vs. Category 2: What Reclassification Actually Means
This is where most of the misinformation lives. Social media is full of posts celebrating that "peptides are legal again" as if you'll be able to walk into a pharmacy and buy BPC-157 off the shelf. That's not how this works. Here's what the FDA reclassification actually changes — and what it doesn't.
What Category 1 Status Means
When a peptide moves to Category 1:
- Licensed compounding pharmacies (under 503A and 503B) can legally prepare it
- A valid prescription from a licensed physician is required
- Pharmacies must follow USP 795/797 compounding standards
- The substance is subject to ongoing regulatory oversight
What Category 1 does not mean:
- It's not over-the-counter availability. You still need a doctor.
- It's not FDA approval. These peptides have not gone through Phase I-III clinical trials, NDA submission, or the full safety and efficacy review that FDA-approved drugs require.
- It's not an endorsement of safety or efficacy by the FDA.
What Category 2 Status Means
Category 2 means the FDA has determined a substance poses "significant safety risks" and compounding pharmacies are prohibited from preparing it. It doesn't make it illegal to possess, and it doesn't criminalize research use. It specifically restricts the pharmacy-to-patient pipeline.
The Distinction That Matters: Compounding Eligibility vs. FDA Approval
FDA approval is a high bar. It requires years of clinical trials, massive datasets, and formal submission through the New Drug Application (NDA) process. Roughly 100 peptide therapeutics have received full FDA authorization — drugs like insulin, semaglutide, teriparatide, and octreotide.
Category 1 status is a much lower bar. It means the FDA has not identified sufficient safety concerns to prohibit compounding. The 14 peptides being reclassified don't join the ranks of FDA-approved drugs. They join the list of substances that compounding pharmacies are allowed to work with.
What This Looks Like in Practice
Once formal reclassification is published:
- You'll need a prescription from a licensed physician
- A compounding pharmacy will prepare the peptide to your doctor's specifications
- Quality control returns to the regulated pharmacy system
- Insurance will almost certainly not cover compounded peptides — expect out-of-pocket costs ranging from roughly $100 to $400 per month depending on the peptide and dosing protocol
The 5 Peptides Expected to Remain Restricted
Not all 19 peptides are coming back. Approximately five are expected to stay on Category 2. Based on analyst consensus and reporting from multiple sources, here's what's likely staying restricted and why.
| Peptide | Likely Reason for Continued Restriction |
|---|---|
| Melanotan II | Cardiovascular concerns; theoretical melanoma risk from melanocyte stimulation; well-documented abuse and misuse potential (primarily used for tanning); multiple adverse event reports |
| GHRP-2 | FDA documented adverse events including deaths; elevates cortisol and prolactin; overlaps with existing FDA-approved growth hormone therapies |
| GHRP-6 | Similar safety profile concerns as GHRP-2; significant appetite stimulation side effects; cortisol elevation |
| LL-37 (Cathelicidin) | Very limited human safety data; complex immune effects that could theoretically worsen autoimmune conditions |
| PEG-MGF (PEGylated Mechano Growth Factor) | PEGylation raises immunogenicity concerns; limited clinical data; potential for misuse in athletic performance |
A note on uncertainty: some sources also flag Ipamorelin and CJC-1295 as potentially remaining restricted pending PCAC review, rather than moving to Category 1 immediately. The September 2024 PCAC referral process for those peptides is still technically ongoing. Until the formal list is published, there's ambiguity here.
And as with the list of 14, this restricted list is based on reporting and analyst interpretation — not an official FDA publication. The formal list may differ.
The Gray Market Problem: Why This Reversal Matters for Safety
The safety argument for reclassification might seem counterintuitive at first. How does making more peptides available make things safer? The answer lies in what happened when they were banned.
What the Ban Created
When compounding pharmacies lost the ability to prepare these peptides, demand didn't disappear. Patients who had been using BPC-157 for gut healing, or Thymosin Alpha-1 for immune support, or CJC-1295/Ipamorelin for hormone optimization didn't simply stop. Many of them turned to the only remaining source: unregulated online vendors selling peptides labeled "for research purposes only."
Kennedy acknowledged this directly: "We created the gray market."
The Scale of the Problem
The gray market that emerged was substantial and poorly controlled. Texas lab testing found that online peptide vendors often sell products that don't match what's advertised — wrong concentrations, wrong peptides, contamination. The FDA's enforcement response reflected the scale: warning letters to research peptide vendors increased dramatically, targeting companies like Summit Research Peptides, Prime Peptides, Swisschems, and Xcel Research, among others.
Why Regulated Access Is Better Than No Access
Compounding pharmacies operating under 503A and 503B work within a regulated framework. They follow USP 795 and 797 standards for compounding and sterility. They're subject to state board of pharmacy oversight. They maintain records. When something goes wrong, there's accountability.
Gray market vendors have none of this. No sterility testing. No consistent manufacturing standards. No oversight. No recourse if a product is contaminated or mislabeled.
Moving peptides back to Category 1 doesn't eliminate risk — it moves risk from unregulated to regulated environments. That's a meaningful distinction.
The Counterargument
Not everyone agrees this is straightforward. Some researchers and physicians argue that even compounded peptides carry real risks given the limited human safety data for many of these substances. Reclassification shouldn't be confused with a safety endorsement.
UC Davis cell biologist Paul Knoepfler, speaking to PolitiFact, put it plainly: "Each of the ten or so most popular peptides remain somewhat of a mystery in terms of their impacts when used in people."
That's an honest assessment. Most peptides on this list have strong preclinical data and varying amounts of clinical evidence, but none have gone through the rigorous Phase III trial process that FDA-approved drugs require. Patients and prescribers should understand this distinction clearly.
What This Means for Different Stakeholders
For Patients Currently Using Peptides from Gray Market Sources
Don't change your approach based on the announcement alone. As of this writing, no formal reclassification has been published. The legal status of these peptides has not changed.
When reclassification does become official, the smart move is straightforward: work with a licensed physician and a compounding pharmacy. Transition from gray market products to regulated compounded versions. Discuss the switch with your prescriber, including any differences in formulation, dosing, or delivery.
For Patients Who Stopped Peptide Therapy After the 2023 Ban
Access is coming back, but it's not back yet. Contact your prescribing physician to discuss resuming therapy once formal reclassification is published. Be prepared for potential cost differences compared to pre-ban pricing — supply chains need to rebuild, and compounding pharmacies will need time to scale back up.
For Physicians and Prescribers
No prescribing changes should be made until formal FDA action is published. In the meantime, this is a good opportunity to prepare patient education materials and review updated compounding pharmacy sourcing options for when access is restored. This connects to the broader regulatory picture covered in our compounding crackdown analysis.
For Compounding Pharmacies
This is important: do not begin compounding Category 2 peptides based on the announcement alone. Wait for a formal Federal Register notice or an official FDA list update. Compounding before that point carries real legal and regulatory risk.
That said, now is the time to prepare. Review supply chain readiness. Update quality assurance protocols. Prepare for rapid scaling when the formal green light comes. And for the five peptides already under PCAC review (CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604, Selank), follow those proceedings closely.
Timeline: From the 2023 Ban to the 2026 Reversal
| Date | Event |
|---|---|
| September 2023 | FDA begins moving peptides to Category 2 on the 503A bulk drug substances list |
| October 2023 - February 2024 | 17 peptides placed on Category 2 list, effectively banning them from compounding |
| Throughout 2024 | Legal challenges from compounding pharmacy industry groups; Outsourcing Facilities Association sues FDA |
| September 2024 | 5 peptides (CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604, Selank) removed from Category 2 and sent to PCAC for review — the first crack in the ban |
| October 2024 | PCAC meeting reviews Ipamorelin under Section 503A |
| December 2024 | PCAC meeting reviews CJC-1295 under Section 503A; total restricted peptides reaches 19 |
| January 2025 | FDA issues revised interim guidance on compounding with bulk drug substances |
| February-March 2025 | GLP-1 medications (semaglutide, tirzepatide) removed from shortage lists, ending the compounding window for those drugs |
| 2025 | ~50% increase in FDA warning letters; enforcement surge against research peptide vendors and compounders |
| December 2025 | SAFE Drugs Act (H.R. 6509) introduced, proposing further compounding restrictions |
| January 20, 2025 | RFK Jr. confirmed as HHS Secretary |
| February 27, 2026 | Kennedy announces on Joe Rogan Experience (#2461) that ~14 peptides will move from Category 2 to Category 1 |
| Coming weeks (TBD) | Formal FDA reclassification expected — not yet published as of March 7, 2026 |
For the complete regulatory history, see our FDA Peptide Regulation: Complete 2025-2026 Timeline.
The Political Context: Why This Is Happening Now
The timing of this announcement didn't happen in a vacuum. Understanding the political dynamics helps explain both why it happened and why you should be careful about what it actually means.
Kennedy has been a vocal critic of what he describes as FDA "bias" against peptides, chelation drugs, and stem cell treatments. Newser reported that he had previously criticized the agency's approach to all three categories. The "Make America Healthy Again" (MAHA) movement, which helped propel Kennedy to the HHS role, has championed peptide access as a health freedom issue. Peptides have become a cultural flashpoint — promoted by wellness influencers, biohackers, podcasters, and public figures.
The choice to announce this on the Joe Rogan Experience rather than through official FDA channels is consistent with Kennedy's broader approach of using media to signal policy direction. It's effective for generating public attention. But it also means the announcement carries a different weight than a Federal Register notice would.
The Legal Reality Check
LumaLex Law published a careful analysis of what has and hasn't changed. Their conclusion is worth quoting directly:
"No FDA rule has changed. No Federal Register notice has been issued removing peptides from Category 2. No statute has been amended."
The HHS Secretary oversees the FDA and can influence policy direction and enforcement priorities. But the Secretary can't unilaterally rewrite federal drug law or bypass the administrative procedures required to formally change regulatory classifications. Political commentary and regulatory action are not the same thing. The announcement signals direction, not completion.
The Bigger Regulatory Picture
This is happening alongside other shifts in the compounding world. The GLP-1 compounding restrictions — the end of compounded semaglutide and tirzepatide after those drugs came off the shortage list — are moving in the opposite direction, tightening access to compounded versions of FDA-approved drugs.
The peptide therapeutics market is projected to reach $49.68 billion in 2026. Both the original ban and its potential reversal are unfolding in a regulatory environment that's moving fast. The regulatory analyst Derek Pruski has argued that the shift from Category 2 to Category 1 reflects a broader reassessment of how the FDA applies the safety signal standard to compounding decisions.
What to Watch For Next
The announcement was the beginning of a process, not the end of one. Here's what to track:
-
The formal FDA publication. The official updated Category 1 and Category 2 lists are the only thing that changes legal status. Everything before that is speculation — informed speculation, but speculation nonetheless.
-
PCAC meetings. The Pharmacy Compounding Advisory Committee will continue reviewing individual peptides. Watch for upcoming meeting schedules and recommendations.
-
The exact list of 14. Until the formal list is published, the specific peptides remain unconfirmed. There could be surprises in either direction.
-
Congressional response. The SAFE Drugs Act (H.R. 6509), introduced in December 2025, proposed further compounding restrictions. Whether it advances or stalls in light of the reversal announcement will signal where legislative momentum is heading.
-
Compounding pharmacy readiness. Supply chains were disrupted by the ban. How quickly pharmacies can source raw materials, validate processes, and resume production will determine how fast patients can actually access these peptides once reclassification is formal.
-
Pricing. Whether increased supply through legal channels reduces gray market activity and brings down prices. Pre-ban compounded peptides were generally affordable; post-ban gray market prices have been higher and more variable.
-
State-level actions. Some states may move faster or slower than federal guidance. Watch for state pharmacy board announcements that could affect access on a state-by-state basis.
The Bottom Line
Here's what you need to know, stripped down to the essentials:
What happened: RFK Jr. announced that approximately 14 peptides will be moved from the FDA's "do not compound" list back to legal compounding status.
What it means: If implemented, this is the most significant expansion of legal peptide access in U.S. history. Peptides like BPC-157, Thymosin Alpha-1, Selank, Semax, and others would once again be available through licensed compounding pharmacies with a prescription.
What hasn't happened yet: No formal rule change. No Federal Register notice. No updated list. The legal status of these peptides has not changed as of this writing.
What you should do: Don't change your healthcare decisions based on a podcast announcement. Wait for formal FDA action. When it comes, work with a licensed physician and an accredited compounding pharmacy. This is not the time to stockpile gray market peptides or make assumptions about what's coming.
What PeptideJournal will do: We'll update this article as formal reclassification is published, PCAC makes additional recommendations, and compounding pharmacies begin production. Bookmark this page or subscribe for updates. This is a developing story, and we'll stay on it.
Frequently Asked Questions
Which 14 peptides are being made legal again?
The expected list includes BPC-157, TB-500, GHK-Cu, Thymosin Alpha-1, KPV, AOD-9604, MOTS-C, Selank, Semax, Epitalon, CJC-1295, Ipamorelin, Kisspeptin-10, and one additional peptide that varies across sources (possibly DSIP, Emideltide, or Sermorelin). The formal FDA list has not been published, so this list may change.
Are peptides FDA approved now?
No. Moving from Category 2 to Category 1 is not FDA approval. It means compounding pharmacies can legally prepare these peptides again. FDA approval requires Phase I-III clinical trials and a formal New Drug Application — a completely different process. For a full list of peptides that do have FDA approval, see our complete list of FDA-approved peptides.
When will the FDA officially reclassify these peptides?
Kennedy indicated the change would happen "within weeks" of his February 27, 2026 announcement. No formal timeline has been confirmed. The reclassification requires an official FDA publication updating the Category 1 and Category 2 lists.
Can I buy peptides legally right now?
Not from compounding pharmacies — Category 2 peptides are still legally restricted for compounding until formal reclassification is published. Research chemical sales continue to exist in a regulatory gray area, but those products lack the quality controls of compounding pharmacy preparations.
Do I need a prescription for these peptides?
Yes. Even after reclassification to Category 1, compounded peptides require a valid prescription from a licensed physician. This is not changing. You will not be able to buy these peptides over the counter.
Will insurance cover compounded peptides?
Almost certainly not. Compounded medications are typically not covered by insurance. Expect to pay out of pocket, with costs ranging from approximately $100 to $400 per month depending on the peptide and dosing protocol.
Which peptides are still banned?
Based on reporting and analyst consensus, Melanotan II, GHRP-2, GHRP-6, LL-37 (Cathelicidin), and PEG-MGF are expected to remain on Category 2. These peptides have more documented safety concerns, including adverse events, cardiovascular risks, and immunogenicity issues. The formal restricted list has not been published.
Is BPC-157 legal again?
Not yet. BPC-157 is expected to be reclassified to Category 1 based on Kennedy's announcement, but as of March 7, 2026, it's still technically on the Category 2 list. Formal reclassification requires an official FDA publication.
What is the difference between Category 1 and Category 2?
Category 1 means a substance is eligible for compounding by licensed pharmacies under Section 503A/503B of the Federal Food, Drug, and Cosmetic Act. Category 2 means the FDA has identified "significant safety risks" and compounding is prohibited. The reclassification moves peptides from the restricted list to the eligible list — but it's not FDA approval and doesn't make them available without a prescription.
What did RFK Jr. actually say about peptides?
On the February 27, 2026 episode of the Joe Rogan Experience (#2461), Kennedy said that approximately 14 of the 19 restricted peptides would be moved from Category 2 to Category 1. He argued the FDA lacked proper safety signals to justify the original restrictions, called them based on missing efficacy data rather than evidence of harm, and admitted the ban had "created the gray market." He said his hope was that the peptides would "get moved to a place where people have access from ethical suppliers."